Chronic urticaria
Therapeutic area
Dermatology
Rare disease
No
- Definition
- An urticaria that is characterized by the presence of urticaria for a period exceeding 6 weeks, assuming symptoms for most days of the week.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Chronic urticaria
- Alternative names
- chronic urticaria
- Therapeutic area
- Dermatology
- Disease mechanisms
- Inflammatory
- All therapeutic areas
- Dermatology
- Severity
- Mild
- MONDO ID
- MONDO:0850230
- Parent condition
- MONDO:0005492
Related records
Broader conditions (9)
- Dermatitis
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Inflammatory disease
- Integumentary system disorder
- Skin disorder
- Urticaria
Narrower conditions (1)
- Chronic inducible urticaria
Trials (186)
- 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
- A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
- A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)
- A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
- A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
- A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
- A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
- A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
- A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
- A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
- A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)
- A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China
- A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
- A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China